Indeed, studies targeting SOD1 and C9orf72 mutations have demonstrated efficacy against preclinical models of ALS, and clinical studies using intrathecal administration of antisense oligonucleotides for these genes are ongoing (Sharma et al., 2017). Here, C9orf72 is linked to amyotrophic lateral sclerosis.